Merck マネジメント

マネジメント基準チェック /34

Merckの CEO はRob Davisで、 Apr2021年に任命され、の在任期間は 4.75年です。の年間総報酬は$ 20.80Mで、 7.9%給与と92.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.018%を直接所有しており、その価値は$ 50.08M 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と6.6年です。

主要情報

Rob Davis

最高経営責任者

US$20.8m

報酬総額

CEO給与比率	7.91%
CEO在任期間	5yrs
CEOの所有権	0.02%
経営陣の平均在職期間	5.3yrs
取締役会の平均在任期間	6.6yrs

経営陣の近況

Recent updates

The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff

Jan 30Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85

Dec 02

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 02

Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

Aug 12

CEO報酬分析

Merck の収益と比較して、Rob Davis の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2025	US$21m	US$2m	US$18b
Sep 30 2025	n/a	n/a	US$19b
Jun 30 2025	n/a	n/a	US$16b
Mar 31 2025	n/a	n/a	US$17b
Dec 31 2024	US$23m	US$2m	US$17b
Sep 30 2024	n/a	n/a	US$12b
Jun 30 2024	n/a	n/a	US$14b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$20m	US$2m	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b

報酬と市場: Robの総報酬 ($USD 20.80M ) は、 US市場 ($USD 14.20M ) の同規模の企業の平均を上回っています。

報酬と収益: Robの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Rob Davis (58 yo)

5yrs

在職期間

US$20,797,845

報酬

Mr. Robert M. Davis, also known as Rob, J.D., is CEO and Director of Merck Sharp & Dohme LLC since July 1, 2021 and has been its Chairman since December 1, 2022. He is Chief Executive Officer and Director...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Davis	Chairman	5yrs	US$20.80m	0.018% $ 50.1m
Caroline Litchfield	Executive VP & CFO	5yrs	US$7.51m	0.0037% $ 10.2m
Jennifer Zachary	Executive VP & General Counsel	8yrs	US$5.86m	0.0028% $ 7.8m
Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	16.4yrs	US$5.41m	0.0081% $ 22.5m
Dean Li	Executive VP & President of Merck Research Laboratories	8.4yrs	US$8.89m	0.0037% $ 10.4m
Dalton Smart	Senior VP of Finance	2.3yrs	データなし	0.00033% $ 920.1k
David Williams	Executive VP and Chief Information & Digital Officer	no data	データなし	0.0013% $ 3.5m
Peter Dannenbaum	Vice President of Investor Relations	6.7yrs	データなし	データなし
Chirfi Guindo	Executive Vice President of Strategic Access	less than a year	US$13.94m	0.0024% $ 6.8m
Betty Larson	Executive VP & Chief Human Resources Officer	2yrs	US$11.26m	0.00025% $ 697.1k
Richard DeLuca	Executive VP & President of Merck Animal Health	14.6yrs	US$9.10m	0.0065% $ 18.1m
Johannes Oosthuizen	Executive VP and President of Oncology & MSD International	5.3yrs	データなし	0.00086% $ 2.4m

5.3yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: MRKの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Davis	Chairman	4.8yrs	US$20.80m	0.018% $ 50.1m
Pamela Craig	Independent Director	10.6yrs	US$405.00k	0.000070% $ 195.2k
Patricia Russo	Independent Director	30.6yrs	US$365.00k	0.00053% $ 1.5m
Thomas Glocer	Independent Lead Director	18.4yrs	US$415.00k	0.00021% $ 585.5k
Risa Lavizzo-Mourey	Independent Director	5.9yrs	US$340.00k	0.000040% $ 111.5k
Douglas Baker	Independent Director	3.9yrs	US$350.00k	0.00065% $ 1.8m
Inge Thulin	Independent Director	8.1yrs	US$340.00k	0.00012% $ 334.6k
Stephen Mayo	Independent Director	5.1yrs	US$350.00k	0% $ 0
Kathy Warden	Independent Director	6.1yrs	US$340.00k	0.000020% $ 55.8k
Christine Seidman	Independent Director	6.1yrs	US$385.00k	0% $ 0
Paul Rothman	Independent Director	10.6yrs	US$405.00k	0% $ 0
Mary Coe	Independent Director	7.1yrs	US$340.00k	0% $ 0

6.6yrs

平均在職期間

66.5yo

平均年齢

経験豊富なボード: MRKの取締役会は経験豊富であると考えられます ( 6.6年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/04/23 18:03
終値	2026/04/23 00:00
収益	2025/12/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Merck & Co., Inc. 21 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。49

アナリスト	機関
David Toung	Argus Research Company
Charles Butler	Barclays
Emily Field	Barclays

Merck マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Merck & Co., Inc., Annual General Meeting, May 26, 2026

Merck & Co., Inc. Announces Executive Appointments and Organizational Changes in Human Health Business

Executive VP & General Counsel notifies of intention to sell stock

Chairman recently sold US$5.6m worth of stock

Chairman notifies of intention to sell stock

Recent updates

Merck and Eisai Enter Announces FDA Approves Merck’S Once-Daily Idvynso (Doravirine/Islatravir)

Merck Announces FDA Grants Priority Review For Keytruda And Keytruda Qlex Each With Padcev For Cisplatin-Eligible Patients With Muscle-Invasive Bladder Cancer

Merck Announces European Commission Approval For Enflonsia (Clesrovimab) For Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Infants

Daiichi Sankyo And Merck Receive Priority Review For Ifinatamab Deruxtecan In Previously Treated Extensive-Stage Small Cell Lung Cancer

Merck & Co., Inc., Annual General Meeting, May 26, 2026

Merck Announces Initiation of Pivotal Phase 2B/3 Trial Evaluating Mk-8748 for Treatment of Neovascular Age-Related Macular Degeneration

Merck Announces Results for Enlicitide Decanoate, an Investigational Oral Pcsk9 Inhibitor

Merck & Co., Inc. Announces Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Merck Reportedly Nears $6 Billion Deal to Buy Terns Pharma

Merck Presents New Data Reinforcing Long-Term Efficacy of Gardasil 9 and Gardasil At Eurogin International Multidisciplinary HPV Congress 2026

Upcoming dividend of US$0.85 per share

Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda

Merck & Co., Inc. Announces KEYTRUDA®? (Pembrolizumab) Plus Padcev®? (enfortumab Vedotin-Ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Ejfv

Merck & Co., Inc. Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL) an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck & Co., Inc. Announces Executive Appointments and Organizational Changes in Human Health Business

Merck Announces Positive New Data for ENFLONSIA (Caresrovimab) for Infants and Children Under 2 Years of Age At Increased Risk for Severe Respiratory Syncytial Virus Disease over Two RSV Seasons

Merck announces Health Canada Approves KEYTRUDA SC™, a Subcutaneous Formulation of Pembrolizumab Across Multiple Cancer Indications

Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium

Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX

Executive VP & General Counsel notifies of intention to sell stock

Chairman recently sold US$5.6m worth of stock

Merck Announces Health Canada Approval of ENFLONSIA for the Prevention of RSV in Newborns and Infants

Chairman notifies of intention to sell stock

Full year 2025 earnings: EPS misses analyst expectations

Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2026

Third quarter dividend of US$0.85 announced

The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff

Merck Declares Dividend on Common Stock for the Second-Quarter of 2026, Payable on April 7, 2026

MSD Reportedly Ends Takeover Talks with Revolution Medicines

Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib in Combination with KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph) in Certain Patients with Advanced NSCLC

Merck Reaches Agreement with U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Merck Announces KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Merck Receives Positive EU Chmp Opinion for Expanded Use of Winrevair™? (Sotatercept) in Adults with Pulmonary Arterial Hypertension (Pah, Who* Group 1 Pulmonary Hypertension)

Upcoming dividend of US$0.85 per share

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

FDA Approves Merck and KEYTRUDA (Pembrolizumab) and KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph

Third quarter dividend increased to US$0.85

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravir (Dor/Isl) in Treatment-1 Infection

Merck Declares Dividend for the First Quarter of 2026, Payable on January 8, 2026

Merck Reportedly Close on A Deal to Buy Cidara

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Adults with Heterozygous Familial Hypercholesterolemia in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Phase 3 CORALreef Lipids Trial

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Merck & Co., Inc. Updates Earnings Guidance for the Year 2025

European Commission Approves KEYTRUDA® (Pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Merck Announces Positive Topline Results from the Phase 3 LITESPARK-022 Trial in Patients with Clear Cell Renal Cell Carcinoma

Merck & Co., Inc. Receives FDA Approval For Updated Indication Of WINREVAIR In Adults With PAH

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio At AHA Scientific Sessions 2025

Merck & Co., Inc. Announces the Presentation of Findings from Systematic Review of Studies on the Ep Epiiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CapvaXIVE

Merck & Co., Inc. Announces New Long-Term Data Highlighting the Sustained Survival Benefits of Keytruda® (Pembrolizumab), Merck’s anti-PD-1 Therapy, in Treating Non-Small Cell Lung Cancer (NSCLC )

Daiichi Sankyo and Merck Demonstrate Clinically Meaningful Response Rates for Raludotatug Deruxtecan in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)

Merck & Co., Inc. Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients with Platinum-Resistant Recurrent Ovarian Cancer

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Early Stages of Disease At ESMO 2025

Merck Expands Tulisokibart Clinical Development Program with Initiation of Phase 2B Trials in Three Additional Immune-Mediated Inflammatory Diseases

Investor sentiment improves as stock rises 15%

Merck Announces Positive Results from the Phase 3 HYPERION Trial Evaluating Winrevair

FDA Approves Merck’s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA (pembrolizumab)

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

Merck & Co., Inc. Announces Positive Results from the Phase 3 STRIDE-13 Trial Evaluating CapvaXIVE

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Upcoming dividend of US$0.81 per share

Merck & Co., Inc. Announces Positive Topline Results from the Phase 3 CORALreef Lipids Trial Evaluating the Safety and Efficacy of Enlicitide Decanoate

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

マネジメント基準チェック /34